Doctors, public health experts, and even Democratic members of Congress are sounding the alarm on a new Biden administration proposal to restrict access to a key addiction-treatment medication. The proposal would curtail access via telehealth to buprenorphine, a common and highly effective drug used to treat opioid use disorder. While doctors can currently give out both new ...

Health insurers’ margins in Medicare Advantage were more than double those seen in other markets in 2021, reinforcing the way the program can produce strong financial returns for plans, a new Kaiser Family Foundation analysis shows. Why it matters: Private Medicare plans are expected to draw more than half of eligible beneficiaries this year. But government payments to ...

California’s state of emergency declaration, a response to the COVID-19 pandemic, ends on February 28. The federal state of emergency also ends this spring, on May 11.

Despite rising costs, employers will continue to offer healthcare coverage to their workers, and they don’t see that ending anytime soon, if ever, according to a report by the Employee Benefit Research Institute (EBRI).

As pandemic-era policies come to an end, tens of thousands of Southern Californians are expected to lose out on Medi-Cal, California’s Medicaid program, come April. Experts estimate about 330,000 people in Los Angeles County and approximately 160,000 in Orange County will be ineligible for Medi-Cal in April when states resume the redetermination process. The number of ...

As reported by Reuters, an analysis by the health care research firm 3 Axis Advisors found a roster of drugmakers raised prices in the U.S. last month on more than 350 drugs. The manufacturers include major industry players like AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline (GSK), Pfizer, and Sanofi.